tci Medicare Compliance & Reimbursement - 2003 Issue 18
Business Arrangements: 5 RED FLAGS FOR DRUGMAKER-DOC BUSINESS ARRANGEMENTS
Subscribe or sign in to view the full article.
Article Overview
This article discusses compliance guidance from the HHS Office of Inspector General for physician and pharmaceutical company business arrangements. It is aimed at readers who need a high-level understanding of anti-kickback risk areas, safe harbor considerations, and the general factors the OIG highlights when evaluating these relationships.
Why This Topic Matters
These arrangements can create compliance exposure if they are structured in ways that raise kickback concerns or create conflicts of interest. The article helps readers recognize the broad risk areas that matter for compliance review and contract scrutiny.
What You Will Learn
- How the OIG frames compliance concerns in physician–drugmaker relationships
- Why safe harbor concepts are relevant to these arrangements
- The broad categories of risk factors the OIG emphasizes in evaluating payment relationships
- How payments, value, and conflicts of interest can affect compliance review at a general level
Who Should Read This
- Physicians
- Pharmaceutical company compliance staff
- Healthcare attorneys
- Medical practice administrators
- Corporate compliance professionals
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.


Quick, Current, Complete - www.findacode.com